Business Wire

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Share

Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investigational treatment, significantly improved signs and symptoms of generalized pustular psoriasis (GPP) in patients experiencing a flare.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GPP is a rare, life-threatening neutrophilic skin disease, which is distinct from plaque psoriasis. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).2,3,4 There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life5 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure and sepsis and even death.6

In the 12-week trial, 53 patients experiencing a GPP flare were treated with a single intravenous dose of spesolimab or placebo. Most patients at the outset of the trial had a high or very high density of pustules and impaired quality of life. Results after one week demonstrated that:

  • 54% of patients treated with spesolimab showed no visible pustules compared to 6% of those treated with placebo;
  • 43% of patients treated with spesolimab showed clear/almost clear skin compared to 11% of those in the placebo group.1

Pustular and skin clearance continued for the duration of the study. This clearance was accompanied by clinically significant improvements in quality of life and symptoms such as pain and fatigue, compared to placebo.1

Over the 12-week duration of the study, non-serious infections rates were higher in the spesolimab group compared with placebo, with no pattern regarding pathogen and affected organs. Two patients reported to have drug reactions with eosinophilia and systemic symptoms.

“With no approved treatments in the U.S. or E.U. for GPP flares, there is a significant unmet need for people with this distressing and painful skin condition, that often requires emergency care,” said Mark Lebwohl, MD, lead investigator and publication author, and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, Kimberly and Eric J. Waldman Department of Dermatology, New York. “These clinical trial results show that spesolimab has the potential to completely clear the skin of the signs and symptoms of a GPP flare after only one week, with sustained effect observed for up to 12 weeks.”

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for the treatment of GPP, and Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares. This designation is for therapies treating serious or life-threatening conditions where early clinical evidence suggests a substantial improvement compared to existing treatments. The Chinese Regulatory Authority Centre for Drug Evaluation (CDE) also recently granted Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares.

“At Boehringer Ingelheim, we are committed to finding transformative therapies to help advance treatment for people who urgently need them,” said Dr Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, Boehringer Ingelheim. “The findings indicate that spesolimab may have a significant and positive impact on patients experiencing a GPP flare.”

The clinical program for spesolimab includes two other trials that are currently underway. First, the Effisayil-2 trial is designed to investigate spesolimab as a maintenance treatment to prevent the occurrence of GPP flares. The Effisayil-ON trial is an open label five-year extension study to investigate the longer term efficacy and safety of spesolimab in patents with GPP.7,8

Please click on the following link for ‘Notes to Editors’: https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/spesolimab-phase-ii-data

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR

Dr Julia Fass
Phone: +49 (6132) 77 95614
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com

Additional information
www.boehringer-ingelheim.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stressed, anxious, excited – CIOs' state of mind in 2024, according to research from Expereo19.9.2024 11:03:00 EEST | Press release

Technology leaders from large global enterprises are feeling the pressure as AI becomes a major force of innovation and disruption, according to the IDC InfoBrief, commissioned by Expereo, Enterprise Horizons 2024: Technology Leaders’ Priorities on Their Digital Business Journey*, which reveals that 64% of global respondents find it challenging and/or stressful to meet the technology demands of the business, and that AI is a key source of both pressure and opportunity. The paper reveals that AI has raised the profile and expectations of technology leaders at board level – a double-edged sword for many senior technology decision-makers. While 60% of global respondents say their focus on AI has boosted their personal reputation, 47% also say their board has unrealistic demands regarding the impact of AI on international business performance and 39% felt their job is more stressful or negative because of their added profile. The perceived impact of AI on the workforce, both within and out

HORNBACH Baumarkt Selects Blue Yonder To Accelerate Its Omni-Channel, Customer-Centric Strategy19.9.2024 10:00:00 EEST | Press release

Today, retail offers a wide range of opportunities. Retailers must consistently focus on the needs of their customers if they want to be successful – even in the future. Tech innovation is accelerating. Consumers want to be free to decide whether they want to shop in the store or via smartphone or computer. Optimally, it should all be connected. Retailers are looking to innovate, add new services, and deliver experiences that consumers love, but they often face a costly and expensive fix because their tech stack was not built for modern experiences with efficiency in mind. That’s why, as a pioneer in innovation and one of the leading DIY retailers in Europe, HORNBACH Baumarkt has selected Blue YonderInventory and Commits Services, part of Blue Yonder Order Management solutions. HORNBACH Baumarkt is the largest and most important subsidiary of HORNBACH Holding. HORNBACH Baumarkt operates DIY megastores with garden centers and online stores in nine European countries. The DIY retail segm

Wolters Kluwer expert to speak at Europe's inaugural Microsoft Fabric Community Conference19.9.2024 09:00:00 EEST | Press release

Wolters Kluwer Tax & Accounting (TAA), a global leader in professional information, software solutions, and services, today announced that Simon Hjortsberg, the company's Manager of Business Intelligence, will be a keynote speaker at Europe's first-ever Microsoft Fabric Community Conference. The anticipated event will take place from September 24 to 27, 2024, at Stockholmsmässan, in Sweden. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918799017/en/ Simon Hjortsberg, Manager, Business Intelligence, Wolters Kluwer Tax & Accounting (Photo: Business Wire) On Wednesday, September 25, Simon Hjortsberg will deliver a presentation on “Sharing Experiences with Fabric Copilot.” As an experienced Global Senior Business Intelligence Analyst, Hjortsberg will delve into the ways generative AI features are transforming data analysis, generating insights, and creating detailed visualizations and reports in Microsoft Fabric and Power BI

Murata Unveils the World’s Smallest Multilayer Ceramic Capacitor with the First 006003-inch Size (0.16mm×0.08mm) Device19.9.2024 09:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has expanded its innovative range of multilayer ceramic capacitors (MLCCs) with yet another groundbreaking addition. Exemplifying Murata’s continual commitment for minimization, it has developed the world’s first 006003-inch size (0.16 mm x 0.08 mm) MLCC. This achievement represents a volume ratio approximately 75% lower than the existing smallest product, the 008004-inch size (0.25×0.125mm). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918232327/en/ [Murata Manufacturing Co., Ltd.] Murata’s world’s first 006003-inch size (0.16 mm x 0.08 mm) MLCC (Photo: Business Wire) In recent years, as electronic devices become more sophisticated and compact, the number of electronic components installed has increased, while simultaneously the space required for installation has been reduced. As electronic devices continue to advance in intelligence, there has been a c

Dfns Wallet Infrastructure Now Available on Temenos Exchange19.9.2024 08:37:00 EEST | Press release

Dfns, a leading provider of wallets-as-a-service (WaaS) solutions, today announced Dfns Wallet Infrastructure is available on Temenos Exchange, the partner ecosystem of integrated fintech solutions. This partnership makes Dfns the first European digital asset infrastructure provider to integrate with Temenos, joining a select group that includes Wyden, Fireblocks, and Taurus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918695901/en/ Dfns Wallet Infrastructure Now Available on Temenos Exchange (Graphic: Business Wire) The Dfns Wallet Infrastructure delivers critical business benefits tailored to the needs of institutional finance and banks. By integrating with Temenos, our solution offers services such as key, authentication, identity and access, blockchain, wallet and transaction management. This partnership differentiates our offering by connecting our secure and compliant wallets with the rigorous standards and busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye